It is also noteworthy that Wu et al. [94] has demonstrated that the Akt inhibitor SC66 attenuates COL11A1-driven chemoresistance in human ovarian cancer cells in vitro and in vivo, making SC66 a promising drug candidate to treat COL11A1-high cancers. This evidence concerns the gene COL11A1 and ovarian cancer.